Global CRO Tigermed has debuted a new international headquarters in Hong Kong in a move to enhance the coordination and management of its worldwide projects.
The company, which had previously been based in Hangzhou, China, established offices in Hong Kong in 2011.
By moving its headquarters to one of the central financial hubs in the Asia-Pacific region, the company hopes to expand its research capabilities and global reach, according to an Aug. 17 press release.
Financial and office space details of the headquarters project weren’t disclosed.
Tigermed boasts more than 10,000 employees across 50 countries, including the Asia-Pacific region, Europe, the Americas and Africa. It was listed on the Hong Kong Stock Exchange in 2020.
“With the international headquarters going into operation, we will continue strengthening the global presence and leveraging unique global layout to enhance service offerings and the connections with partners worldwide, and serve as a bridge to advance healthcare breakthroughs for patients,” Xiaoping Ye, M.D., Tigermed co-founder and chairman, said in the release.
The company jumped to prominence as a major CRO player in 2013 following a successful collaboration with Celgene and the approval of Revlimid in China, which is used to treat multiple myeloma.